RSI Overbought Stocks
ERAS is RSI overbought, meaning strong buying pressure may lead to a short-term consolidation or pullback.
ERASCA INC (ERAS) Stock Price & Overview
NASDAQ:ERAS • US29479A1088
Current stock price
17.81 USD
+1.21 (+7.29%)
At close:
17.98 USD
+0.17 (+0.95%)
After Hours:
The current stock price of ERAS is 17.81 USD. Today ERAS is up by 7.29%. In the past month the price increased by 14.61%. In the past year, price increased by 1435.34%.
ERAS Key Statistics
52-Week Range1.01 - 18.18
Current ERAS stock price positioned within its 52-week range.
1-Month Range12.91 - 18.18
Current ERAS stock price positioned within its 1-month range.
- Market Cap
- 5.535B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.44
- Dividend Yield
- N/A
ERAS Stock Performance
Today
+7.29%
1 Week
+17.48%
1 Month
+14.61%
3 Months
+396.10%
Longer-term
6 Months +635.95%
1 Year +1,435.34%
2 Years +786.07%
3 Years +545.29%
5 Years N/A
10 Years N/A
ERAS Stock Chart
ERAS Stock Screens
ERAS currently appears in the following ChartMill screener lists.
ERAS Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ERAS. When comparing the yearly performance of all stocks, ERAS is one of the better performing stocks in the market, outperforming 99.83% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
ERAS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ERAS. While ERAS has a great health rating, there are worries on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
ERAS Earnings
Next Earnings DateMay 11, 2026
Last Earnings DateMar 12, 2026
PeriodQ4 / 2025
EPS Reported-$0.10
Revenue Reported
EPS Surprise 8.37%
Revenue Surprise %
ERAS Forecast & Estimates
17 analysts have analysed ERAS and the average price target is 14.99 USD. This implies a price decrease of -15.81% is expected in the next year compared to the current price of 17.81.
Analysts
Analysts81.18
Price Target14.99 (-15.83%)
EPS Next Y-8.03%
Revenue Next YearN/A
ERAS Groups
Sector & Classification
ERAS Financial Highlights
Over the last trailing twelve months ERAS reported a non-GAAP Earnings per Share(EPS) of -0.44. The EPS increased by 40.54% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-124.55M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.44% | ||
| ROE | -38.3% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%9.09%
Sales Q2Q%N/A
EPS 1Y (TTM)40.54%
Revenue 1Y (TTM)N/A
ERAS Ownership
Ownership
Inst Owners68.62%
Shares310.80M
Float254.93M
Ins Owners6.73%
Short Float %10.33%
Short Ratio4.93
ERAS Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ERAS
Company Profile
Erasca, Inc. is a clinical stage precision oncology company. The company is headquartered in San Diego, California and currently employs 103 full-time employees. The company went IPO on 2021-07-15. The firm is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The firm has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
Company Info
IPO: 2021-07-15
ERASCA INC
3115 Merryfield Row, Third Floor
San Diego CALIFORNIA US
Employees: 103
Phone: 18584656511
ERASCA INC / ERAS FAQ
Can you describe the business of ERASCA INC?
Erasca, Inc. is a clinical stage precision oncology company. The company is headquartered in San Diego, California and currently employs 103 full-time employees. The company went IPO on 2021-07-15. The firm is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The firm has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
What is the current price of ERAS stock?
The current stock price of ERAS is 17.81 USD. The price increased by 7.29% in the last trading session.
Does ERASCA INC pay dividends?
ERAS does not pay a dividend.
What is the ChartMill rating of ERASCA INC stock?
ERAS has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is ERAS stock listed?
ERAS stock is listed on the Nasdaq exchange.
How is the market expecting ERAS stock to perform?
17 analysts have analysed ERAS and the average price target is 14.99 USD. This implies a price decrease of -15.81% is expected in the next year compared to the current price of 17.81.